Computerized determination of growth kinetic curves and doubling times from cells in microculture

Reile, Herta; Birnböck, Herbert; Bernhardt, Günther; Spruß, Thilo; Schönenberger, Helmut

doi:10.1016/0003-2697(90)90454-h

Cited by 107 publications

(94 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sorenson's buer (0.025 M sodium citrate, 0.025 M citric acid in 50% ethanol) 0.1 ml was added to each well and the plates were analysed in an ELISA plate reader at 540 nm wavelength. Absorbance at this wavelength correlates closely to absolute cell number (Gillies et al, 1986;Reile et al, 1990;Flick and Giord, 1984). The fraction of surviving cells relative to control were plotted against the log of drug concentration and the IC 50 was interpolated from the resulting sigmoidal curve using a 4-parameter curve ®t (SOFTmax; Molecular Devices Corporation, Menlo Park, CA).…”

Section: Cell Proliferation Assaysmentioning

confidence: 91%

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

et al. 1997

View full text Add to dashboard Cite

Recent studies indicate that oncogenes may be involved in determining the sensitivity of human cancers to chemotherapeutic agents. To de®ne the eect of HER-2/neu oncogene overexpression on sensitivity to chemotherapeutic drugs, a full-length, human HER-2/neu cDNA was introduced into human breast and ovarian cancer cells. In vitro dose-response curves following exposure to 7 dierent classes of chemotherapeutic agents were compared for HER-2-and control-transfected cells. Chemosensitivity was also tested in vivo for HER-2-and control-transfected human breast and ovarian cancer xenografts in athymic mice. These studies indicate that HER-2/neu overexpression was not sucient to induce intrinsic, pleomorphic drug resistance. Furthermore, changes in chemosensitivity pro®les resulting from HER-2/neu transfection observed in vitro were cell line speci®c. In vivo, HER-2/neu-overexpressing breast and ovarian cancer xenografts were responsive to dierent classes of chemotherapeutic drugs compared to control-treated xenografts with no statistically signi®cant dierences between HER-2/neu-overexpressing and nonoverexpressing xenografts. We found no instance in which HER-2/neu-overexpressing xenografts were rendered more sensitive to chemotherapeutic drugs in vivo. HER-2/neu-overexpressing xenografts consistently exhibited more rapid regrowth than control xenografts following initial response to chemotherapy suggesting that a high rate of tumor cell proliferation rather than intrinsic drug resistance may be responsible for the adverse prognosis associated with HER-2/neu overexpression in human cancers.

show abstract

Section: Cell Proliferation Assaysmentioning

confidence: 91%

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

et al. 1997

View full text Add to dashboard Cite

show abstract

“…For in vitro proliferation assays, the cells were seeded into 96-well microplates and cultured for 24 h before adding various test substances to the medium. After another 72 h, in vitro cell growth was estimated by using Crystal violet as described (38) or by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay as described (39). The results were calculated as percent T͞C, where T ϭ OD of treated cultures and C ϭ OD of control cultures ϫ 100.…”

Section: Iverse Antagonistic Analogs Of Growth Hormone (Gh)-mentioning

confidence: 99%

The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas

Busto

Schally

Varga

et al. 2002

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Splice variants (SVs) of receptors for growth hormone-releasing hormone (GHRH) have been found in primary human prostate cancers and diverse human cancer cell lines. GHRH antagonists inhibit growth of various experimental human cancers, including pancreatic and colorectal, xenografted into nude mice or cultured in vitro, and their antiproliferative action could be mediated in part through SVs of GHRH receptors. In this study we examined the expression of mRNA for GHRH and for SVs of its receptors in tumors of human pancreatic, colorectal, and gastric cancer cell lines grown in nude mice. mRNA for both GHRH and SV1 isoform of GHRH receptors was expressed in tumors of pancreatic (SW1990, PANC-1, MIA PaCa-2, Capan-1, Capan-2, and CFPAC1), colonic (COLO 320DM and HT-29), and gastric (NCI-N87, HS746T, and AGS) cancer cell lines; mRNA for SV2 was also present in Capan-1, Capan-2, CFPAC1, HT-29, and NCI-N87 tumors. In proliferation studies in vitro, the growth of pancreatic, colonic, and gastric cancer cells was stimulated by GHRH(1-29)NH2 and inhibited by GHRH antagonist JV-1-38. The stimulation of some gastroenteropancreatic cancer cells by GHRH was followed by an increase in cAMP production, and GHRH antagonist JV-1-38 competitively inhibited this effect. Our study indicates the presence of an autocrine͞paracrine stimulatory loop based on GHRH and SV1 of GHRH receptors in human pancreatic, colorectal, and gastric cancers. The finding of SV1 receptor in human cancers provides an approach to an antitumor therapy based on the blockade of this receptor by specific GHRH antagonists.

show abstract

“…The in vitro testing of the platinum complexes for antitumor activity was carried out on exponentially dividing human cancer cells, according to a previously published microtiter assay [29,43]. Briefly, in 96-well microtiter plates, 100 µL of a cell suspension at 7700 cells/mL culture medium (MCF-7) or 3200 cells/mL (MDA-MB 231) or 2700 cells/mL (LwCaP/FGC) was plated into each well and incubated at 37°C for 3 days (MCF-7, MDA-MB 231) or 5 days (LwCaP/FGC) in a humidified atmosphere (5 % CO 2 ).…”

Section: In Vitro Chemosensitivity Assaysmentioning

confidence: 99%

“…After the proper incubation time, the medium was removed, the cells were fixed with a glutardialdehyde solution and stored under phosphate buffered saline (PBS) at 4°C. Cell biomass was determined by a crystal violet staining technique, as described earlier [29,43]. A microplate reader at 590 nm (Flashscan AnalytikJena AG) was used for the automatic estimation of the optical density of the crystal violet extract in the wells.…”

Section: In Vitro Chemosensitivity Assaysmentioning

confidence: 99%

Enantiomerically Pure [1, 2‐Diamino‐1‐(4‐fluorophenyl)butane]platinum(II) Complexes: Synthesis and Antitumor Activity against MCF‐7 and MDA‐MB 231 Breast Cancer and LnCaP/FGC Prostate Cancer Cell Lines

Dullin

Dufrasne

Gelbcke

et al. 2004

Archiv der Pharmazie

View full text Add to dashboard Cite

Germany b Laboratoire de ChimieEnantiomerically pure 1,2-diamino-1-(4-fluorophenyl)butanes were synthesized Pharmaceutique Organique, by stereoselective procedures. The enantiomeric purity was determined by 1 H Institut de Pharmacie, NMR spectroscopy after derivatization with (1R)-myrtenal. For the coordination Université Libre de Bruxelles, to platinum, the diamines were reacted with K 2 PtI 4 . Reaction with Ag 2 SO 4 Bruxelles, Belgium yielded the respective sulfatoplatinum(II) complexes, which were converted into the dichloroplatinum(II) complexes by treatment with 2 N HCl. The influence of the configuration and the kind of leaving group on the antitumor activity was studied on the MCF-7 and MDA-MB 231 breast cancer cell lines, as well as on the LnCaP/FGC prostate cancer cell line. It was demonstrated that the dichloroplatinum(II) complexes were more active than the respective diiodoplatinum(II) derivatives. Conversion into the sulfatoplatinum(II) complexes further enhanced the antiproliferative effects. The configuration determined the antitumor effects, dependent on the cell line used: : (R,R) > (S,S) > (R,S) > (S,R); MDA-MB 231: (S,S) > (R,R) > (R,S) = (S,R); LnCaP/FGC: (S,S) > (R,R) > (R,S) > (S,R). Keywords IntroductionSince the discovery of the cytotoxicity of platinum complexes by Rosenberg et al. [1], numerous diaminedichloroplatinum(II) complexes have been synthesized and tested for antitumor activity.Cisplatin exhibits high antitumor activity, but its clinical use is mostly limited by toxic side effects [2]. Exchange of both chlorides by cyclobutane-1,1-dicarboxylate led to carboplatin, which showed higher water solubility and reduced toxic side effects; however, myelosuppression and the development of resistance are intolerable disadvantages [3].In order to overcome these drawbacks and to enhance the tumor selectivity, many carrier ligands were developed and coordinated to platinum. The most successful ligand, the 1,2-diaminocyclohexane (DACH), made oxaliplatin to the first platinum-based drug licensed for the therapy of colorectal cancer [4]. It has also shown The cytotoxic potency of Ph/Me-PtCl 2 decreased in the series (R,R) > (S,S) > (S,R) = (R,S), while in the case of 4F-Ph/Me-PtCl 2 , the S,S-enantiomer is more active than its isomers.Because of these studies, we focussed our attention on the 4-F derivatives and determined the influence of the elongation of the C2-alkyl chain (methyl Ǟ ethyl), as well as the significance of the leaving groups, on Scheme 2. Synthesis of 1R,2R-configurated 1,2-diamino-1-(4-fluorophenyl)butanes. Reagents and conditions: a: BOC anhydride (1.1 eq.), TEA (1.1 eq.), CH 2 Cl 2 , O°C to room temperature; b: DMSO (2 eq.), oxalyl chloride (1 eq.), TEA (5 eq.), CH 2 Cl 2 , Ϫ60°C; c: benzylhydroxylamine (1 eq.), MgSO 4 (1 eq.), CH 2 Cl 2 , room temperature; d: 4F-phenylmagnesium bromide (3 eq.), THF, Ϫ50°C; e: column chromatography, petroleum ether ( Results SynthesisThe 1S Using the (2S)-2-aminobutanol (2S)-1, diamine (1S,2S)-13 was available.The optical purity of th...

show abstract

Computerized determination of growth kinetic curves and doubling times from cells in microculture

Cited by 107 publications

References 8 publications

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas

Enantiomerically Pure [1, 2‐Diamino‐1‐(4‐fluorophenyl)butane]platinum(II) Complexes: Synthesis and Antitumor Activity against MCF‐7 and MDA‐MB 231 Breast Cancer and LnCaP/FGC Prostate Cancer Cell Lines

Contact Info

Product

Resources

About